Prevalence and prognostic impact of aortic stenosis in wild-type transthyretin cardiac amyloidosis

17 May 2025 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Mr Hugo Malerbi

Toulouse Rangueil University Hospital of Toulouse, Toulouse (France)

4 More presentations in this session

Presentation thumbnail

Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: the role of overlap with arrhythmogenic cardiomyopathy

Doctor A. Aimo (Pisa, IT)

Abstract Slides Video

Presentation thumbnail

Towards a prognostically meaningful definition of non-dilated left ventricular cardiomyopathy

Doctor A. Aimo (Pisa, IT)

Abstract Slides Video

Presentation thumbnail

Relation of reduced left ventricular global longitudinal strain with exercise pulmonary hypertension and clinical implication in rheumatic mitral stenosis

Doctor S. Lee (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

Predictors of right ventricular dysfunction in patients with surgical repair of Tetralogy of Fallot - significance of biomarkers

Assistant Professor E. Begic (Sarajevo, BA)

Abstract Slides Video

Access the full session

Session thumbnail

Diagnosis and prognosis in cardiomyopathies and valvular disease

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025

You may be interested in

Congress Presentation

Distribution and prognostic impact of left and right systolic and diastolic functions in wild-type transthyretin amyloid cardiomyopathy

Congress Presentation

Severe aortic stenosis in old and very old heart failure patients. What happens when threre is no TAVI

Congress Presentation

Cardiac amyloidosis Echo-Score for patients with severe aortic stenosis. The AMY-TAVI trial.

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources